OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OPRX OptimizeRx Corporation

Trading 04-24 13:04:47 EDT

6.47

+0.06

+0.86%

High6.56	Low6.32	Vol130.95K
Open6.40	D1 Closing6.41	Amplitude3.81%
Mkt Cap121.28M	Tradable Cap92.55M	Total Shares18.76M
T/O842.49K	T/O Rate0.91%	Tradable Shares14.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OPRX","market":"US","secType":"STK","nameCN":"OptimizeRx Corporation","latestPrice":6.465,"timestamp":1777050244007,"preClose":6.41,"halted":0,"volume":130949,"delay":0,"changeRate":0.008580343213728504,"floatShares":14315107,"shares":18759600,"eps":0.269999,"marketStatus":"Trading","change":0.055,"latestTime":"04-24 13:04:47 EDT","open":6.4,"high":6.56,"low":6.316,"amount":842493.5870715,"amplitude":0.038066,"askPrice":6.48,"askSize":235,"bidPrice":6.45,"bidSize":4630,"shortable":3,"etf":0,"ttmEps":0.269999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777060800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.41,"preHourTrading":{"tag":"盘前","latestPrice":6.42,"preClose":6.41,"latestTime":"09:20 EDT","volume":998,"amount":6457.345428,"timestamp":1777036803095,"change":0.01,"changeRate":0.00156,"amplitude":0.028081},"postHourTrading":{"tag":"盘后","latestPrice":6.35,"preClose":6.41,"latestTime":"19:18 EDT","volume":625,"amount":4020.833,"timestamp":1776986280002,"change":-0.06,"changeRate":-0.00936,"amplitude":0.032761},"volumeRatio":0.461752,"impliedVol":1.2448,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/OPRX/wiki","defaultTab":"wiki","newsList":[{"id":"2629028506","title":"OptimizeRx files Form 3 for director Presti Mariyamma Varghese","url":"https://stock-news.laohu8.com/highlight/detail?id=2629028506","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629028506?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:58","pubTimestamp":1776869887,"startTime":"0","endTime":"0","summary":"OptimizeRx filed an initial Form 3 naming Presti Mariyamma Varghese as a director, dated April 3, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL4tXrDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628467052","title":"Myomo appoints Will Febbo to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2628467052","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628467052?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:09","pubTimestamp":1776370184,"startTime":"0","endTime":"0","summary":"Myomo appointed William “Will” Febbo to board of directors effective April 14, 2026; he will serve until 2028 annual meeting of stockholders.Board size increases to six directors with Febbo’s addition.Febbo is CEO and director of Performance Health Systems, which he joined in February 2026.He previously served as CEO of OptimizeRx from 2015 to 2024, leading revenue growth to $92 million from $5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief via Business Wire  on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL3G2PtX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","MYO","BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626924741","title":"OptimizeRx names Microsoft Health & Life Sciences COO Mary Varghese Presti to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2626924741","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626924741?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:05","pubTimestamp":1775678739,"startTime":"0","endTime":"0","summary":"OptimizeRx appointed Mary Varghese Presti to board as independent director on April 8, 2026.Board refresh expands director slate as company shifts toward more integrated, product-led platform with higher recurring subscription revenue.Varghese Presti is corporate vice president, chief operating officer of Microsoft Health & Life Sciences, leading operational strategy for global business.Her background includes leadership roles at Nuance, IBM Watson Health, athenahealth, Pfizer.Company expects her experience in M&A diligence, post-deal integration, platform scaling to support product portfolio expansion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b55061e77cd8620a1463d5a62e5f9961","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9FMNR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","IE000M9KFDE8.USD","LU0225771236.USD","LU0321505868.SGD","SG9999001176.USD","LU1066051498.USD","SG9999014021.USD","BK4592","LU1057294990.SGD","IE00BGHQF748.EUR","SG9999001176.SGD","BK4167","IE00BLSP4239.USD","LU1023059063.AUD","LU1066053197.SGD","LU1894683264.USD","LU0314104364.USD","SG9999003800.SGD","LU0225284248.USD","SG9999014013.SGD","SGXZ57979304.SGD","IE00BKPKM429.USD","LU0321505439.SGD","LU1883839398.USD","LU0234572021.USD","LU0306807586.USD","BK4599","LU0456855351.SGD","LU0985481810.HKD","BK4568","BK4581","IE00B19Z3581.USD","LU0306806265.USD","SG9999002232.USD","BK4585","BK4534","LU0058720904.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4533","BK4007","IE00B3QW5Z07.USD","MSFT","IE00BBT3K403.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU1894683348.USD","SG9999013999.USD","SG9999014039.USD","LU0122379950.USD","LU0170899867.USD","BK4550","IE00B19Z3B42.SGD","IE00BN0W2V16.EUR","LU0868494617.USD","LU2095319765.USD","IE0002270589.USD","BK4588","IE00BN0W2W23.USD","LU0289739699.SGD","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626792507","title":"Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Curis (CRIS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626792507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626792507?lang=en_us&edition=fundamental","pubTime":"2026-04-09 00:50","pubTimestamp":1775667004,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OptimizeRx (OPRX) and Curis (CRIS) with bullish sent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-optimizerx-oprx-and-curis-cris-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-optimizerx-oprx-and-curis-cris-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","BK4588","XBI","BK4167","BK4585","LU0128526141.USD","CRIS","OPRX","BK4581","HCSG","BK4137","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623243223","title":"OptimizeRx replaces auditor UHY with Grant Thornton after internal control weakness disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2623243223","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623243223?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:30","pubTimestamp":1774906235,"startTime":"0","endTime":"0","summary":"OptimizeRx dismissed auditor UHY, effective March 25, 2026.Grant Thornton was engaged as new independent auditor for fiscal 2026, effective March 26, 2026.Audit reports for 2025 and 2024 carried no adverse opinion, disclaimer, or qualification.Company previously disclosed a material weakness tied to controls over completeness and accuracy of data from third-party service organizations.No disagreements with UHY were reported; material weakness did not trigger a financial statement restatement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exch","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5P2HQs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620472059","title":"OptimizeRx publishes corporate presentation on its Dynamic Audience Activation Platform and FY2026 guidance of USD 109-114 million revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2620472059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620472059?lang=en_us&edition=fundamental","pubTime":"2026-03-18 02:32","pubTimestamp":1773772322,"startTime":"0","endTime":"0","summary":"OptimizeRx publishes corporate presentation on its Dynamic Audience Activation Platform and FY2026 guidance of USD 109-114 million revenue. OptimizeRx released a corporate presentation outlining its Dynamic Audience Activation Platform  and its use in predictive, privacy-focused marketing across healthcare professional and patient channels. The presentation said DAAP deals typically range between about USD 0.5 million and USD 1.5 million. OptimizeRx reported a stock price of USD 5.93 and a market capitalization of about USD 111.3 million. The presentation listed cash and cash equivalents of USD 23.4 million and total debt of USD 25.7 million. OptimizeRx also reported net revenue retention of 116% and revenue per average full-time employee of USD 839,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbt3xwh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617634692","title":"OptimizeRx Price Target Cut to $11.00/Share From $28.00 by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2617634692","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617634692?lang=en_us&edition=fundamental","pubTime":"2026-03-07 01:14","pubTimestamp":1772817240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 12:14 ET (17:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"OptimizeRx Price Target Cut to $11.00/Share From $28.00 by B. Riley Securities","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617651631","title":"OptimizeRx Is Maintained at Equal-Weight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617651631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617651631?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:09","pubTimestamp":1772813340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 11:09 ET (16:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636827","title":"OptimizeRx trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617636827?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:37","pubTimestamp":1772807838,"startTime":"0","endTime":"0","summary":"09:31 EST OptimizeRx (OPRX) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635436","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:31 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635436","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617635436?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:31","pubTimestamp":1772807469,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:31 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nAQN2LP2UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663890","title":"B. Riley Adjusts OptimizeRx Price Target to $11 From $28, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663890","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617663890?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:29","pubTimestamp":1772803785,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) has an average rating of Buy and mean price target of $19.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617802946","title":"OptimizeRx price target lowered to $18 from $32 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802946","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802946?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:55","pubTimestamp":1772801755,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on OptimizeRx (OPRX) to $18 from $32 and keeps a Buy rating on the shares after it’s below-consensus r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-18-from-32-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-18-from-32-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617557140","title":"BRIEF-Optimizerx Corp Enters Amendment No. 4 To Financing Agreement- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557140","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617557140?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:09","pubTimestamp":1772748566,"startTime":"0","endTime":"0","summary":"BRIEF-Optimizerx Corp Enters Amendment No. 4 To Financing Agreement- SEC FilingMarch 5  - SEC Filing:OPTIMIZERX CORP - ENTERS AMENDMENT NO. 4 TO FINANCING AGREEMENT ON MARCH 2, 2026 - SEC FILINGOPTIMIZERX CORP - EXTENDS MATURITY DATE OF FINANCING AGREEMENT TO OCTOBER 11, 2029 - SEC FILINGOPTIMIZERX CORP - PERMITS REPURCHASE OF UP TO $10 MILLION IN COMMON STOCK BEFORE MARCH 15, 2027 - SEC FILINGSource text: [ID:n0001448431-26-000002]Further company coverage: OPRX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT1HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617979571","title":"OptimizeRx Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617979571","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617979571?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:02","pubTimestamp":1772748148,"startTime":"0","endTime":"0","summary":"OptimizeRx Corp reports results for the quarter ended December 31 - Earnings SummaryOptimizeRx Corp OPRX.OQ reported quarterly adjusted earnings of 51 cents per share for the quarter ended December 31","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT2XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617579152","title":"OptimizeRx Corp - Enters Amendment No. 4 to Financing Agreement on March 2, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617579152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617579152?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:37","pubTimestamp":1772746666,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT1HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617112579","title":"OptimizeRx Corp - Permits Repurchase of up to $10 Mln in Common Stock Before March 15, 2027 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617112579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617112579?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:37","pubTimestamp":1772746666,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT1HI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617637576","title":"OptimizeRx Q4 revenue stable, beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617637576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617637576?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:12","pubTimestamp":1772745129,"startTime":"0","endTime":"0","summary":"OptimizeRx Q4 revenue stable, beats estimatesOverviewHealthcare tech firm's Q4 revenue stable at $32.2 mln, beating analyst expectationsAdjusted EBITDA for Q4 hit record $12 mln, exceeding analyst est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT1DN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617576092","title":"OptimizeRx reports Q4 EPS 51c, consensus 22c","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576092","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576092?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:11","pubTimestamp":1772745094,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $32.24M, consensus $30.91M. Stephen Silvestro, OptimizeRx (OPRX) CEO commented, “We delivered a strong fourth quarter, exceeding...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-reports-q4-eps-51c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-reports-q4-eps-51c-consensus-22c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617091576","title":"OptimizeRx announces $10M share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2617091576","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617091576?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:10","pubTimestamp":1772745039,"startTime":"0","endTime":"0","summary":"OptimizeRx’s (OPRX) board of directors has authorized a share repurchase program for up to $10M of the company’s outstanding common stock. This sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-announces-10m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-announces-10m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617575102","title":"OptimizeRx posts FY 2025 GAAP net income of USD 5.1 million from a net loss in FY 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2617575102","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617575102?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:02","pubTimestamp":1772744532,"startTime":"0","endTime":"0","summary":"OptimizeRx  reported Q4 2025 revenue of USD 32.2 million, with gross profit up 9% to USD 24.1 million. Q4 net income was USD 5.0 million and adjusted EBITDA reached USD 12.0 million. For FY 2025, OptimizeRx posted revenue of USD 109.4 million , gross profit of USD 73.6 million, net income of USD 5.1 million, and adjusted EBITDA of USD 24.3 million. Cash and cash equivalents were USD 23.4 million at December 31, 2025, and net cash provided by operating activities was USD 18.7 million for FY 2025. The company updated FY 2026 guidance to revenue of USD 109 million to USD 114 million and adjusted EBITDA of USD 21 million to USD 25 million. OptimizeRx also said it paid down an incremental USD 2.0 million in term-loan principal during Q4 and its board authorized a USD 10.0 million share repurchase program, effective March 12, 2026 through March 15, 2027 . Management cited increased market volatility tied in part to uncertainty around Most Favored Nation pricing, and highlighted its AI-driven","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL4zv6ws:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","BK4112","OPRX","LU0314104364.USD","SG9999014039.USD","SG9999014021.USD","BK4167","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.optimizerx.com","stockEarnings":[{"period":"1week","weight":-0.0346},{"period":"1month","weight":-0.0546},{"period":"3month","weight":-0.4622},{"period":"6month","weight":-0.7043},{"period":"1year","weight":-0.2378},{"period":"ytd","weight":-0.4772}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":0.0846},{"period":"3month","weight":0.0279},{"period":"6month","weight":0.0461},{"period":"1year","weight":0.3232},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.043426},{"month":2,"riseRate":0.5,"avgChangeRate":-0.003414},{"month":3,"riseRate":0.25,"avgChangeRate":-0.024049},{"month":4,"riseRate":0.625,"avgChangeRate":-0.046342},{"month":5,"riseRate":0.571429,"avgChangeRate":0.132195},{"month":6,"riseRate":0.857143,"avgChangeRate":0.069942},{"month":7,"riseRate":0.25,"avgChangeRate":-0.03341},{"month":8,"riseRate":0.625,"avgChangeRate":0.055887},{"month":9,"riseRate":0.5,"avgChangeRate":0.066303},{"month":10,"riseRate":0.375,"avgChangeRate":-0.045261},{"month":11,"riseRate":0.5,"avgChangeRate":0.019799},{"month":12,"riseRate":0.25,"avgChangeRate":-0.029069}],"exchange":"NASDAQ","name":"OptimizeRx Corporation","nameEN":"OptimizeRx Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OptimizeRx Corporation,OPRX,OptimizeRx Corporation股票,OptimizeRx Corporation股票老虎,OptimizeRx Corporation股票老虎国际,OptimizeRx Corporation行情,OptimizeRx Corporation股票行情,OptimizeRx Corporation股价,OptimizeRx Corporation股市,OptimizeRx Corporation股票价格,OptimizeRx Corporation股票交易,OptimizeRx Corporation股票购买,OptimizeRx Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction